Lobaplatin (** Lobaplatin (generic name) - Primarily available in China and some Asian markets - Not yet approved by FDA or EMA **)
Chemotherapy
Description
Lobaplatin is used in the treatment of colorectal cancer (CRC), particularly in combination with other agents. It has shown efficacy in clinical trials as a single agent or in combination therapy for advanced CRC patients who have failed prior chemotherapy regimens; however, its use remains limited to certain regions.
Mechanism of Action
Lobaplatin is a third-generation platinum-based anticancer agent that forms intrastrand DNA cross-links and interstrand DNA cross-links, thereby inhibiting DNA replication and transcription.
Side Effects
Myelosuppression; nausea and vomiting; alopecia; nephrotoxicity
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
NCT04845490
Phase 2
Not yet recruiting
Comparative Study of Mitomycin and Lobaplatin in Advanced Colorectal Cancer Patients With Radical Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy